Fund 3
New fund Vesalius Biocapital III

This new fund, launched in May 18th 2017, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

Over €70 million of commitments secured

The fund secured over €70 million of commitments in a first closing in May 2017.



News for Vesalius Biocapital Fund 3

Forendo: Positive Phase 1a Results
read more
Mecuris GmbH: Financing EUR 3.6m
read more
Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate
read more